Pre Seed · Biotech · Oxford, United Kingdom · Founded 2021 · 11–50 employees
Sensible Biotechnologies is developing a novel cell‑based platform to design, optimise and manufacture high‑quality, low‑immunogenicity mRNA within living cells, aiming to overcome the limitations of conventional in vitro transcription methods. The company secured a US$4.2 million pre‑seed financing round in April 2023 led by BlueYard Capital with participation from Y Combinator, Amino Collective, Civilization Ventures, Recode Health Ventures and ZAKA, signalling strong investor confidence. It also announced an AI‑powered acceleration of mRNA optimisation workflows, reducing cycle times by more than 90 percent through integration with NVIDIA accelerated computing. Sensible operates across Oxford, Bratislava and Boston, underlining its international footprint and cross‑border research capabilities.
No open roles listed right now.